- Market Realist•12 days ago
On July 1, 2016, Alnylam Pharmaceuticals (ALNY) published positive preliminary results from its Phase 2 open label extension (or OLE) study.
Alnylam Pharmaceuticals, Inc.NasdaqGS
After hours: 66.210.01 (0.02%) as of 4:41 PM EDT
|Bid||64.10 x 600|
|Ask||70.00 x 100|
|52wk Range||49.96 - 132.00|
|Day's Range||60.47 - 66.47|
|Avg Vol (3m)||932,260|
As of 4:00 PM EDT. Market closed.